The GLP-1 Line Item Is Showing Up in Chemicals, Automation, and Doughnuts

GLP-1s stopped being a pharma story months ago. The compound now turns up in a flavor house's R&D commentary, an industrial automation call, an EHR vendor's outcomes case study, and a doughnut company's investor Q&A — sometimes as the headline, sometimes as one sentence buried in a risk factor nobody would think to search for. SeventhBiz tracks every mention verbatim, tagged to the speaker and the filing, because that's the only way to tell a real demand signal from a company reaching for relevance.

The Direct Effects Are Quantified Now, Not Just Flagged

Intuitive Surgical moved from acknowledging pressure to naming a number in the space of one quarter:

"US da Vinci bariatric cases continued to feel the impact of rising GLP 1 usage declining high single digits during the quarter." (ISRG)

ResMed is running the opposite direction with its own figure attached:

"Patients who have scripts for both PAP and GLP-1s are approximately eleven percent more likely to start on PAP therapy than patients who have a script for PAP alone." (RMD)

Becton Dickinson quantifies the delivery-hardware side of the same trade:

"We now have approximately 100 agreements signed across novel and biosimilar GLP-1 programs... the launch of a semaglutide therapy, utilizing our Vystra injection pen." (BDX)

And Dexcom is citing clinical data to argue its device isn't a substitution risk at all, but a complement:

"The largest relative improvement in A1C was within the cohort using only GLP-1 therapies. This data only further reinforces the complementary relationship between CGM and incretin therapy." (DXCM)

Four companies, four different positions relative to the same drug class, each backed by a specific figure rather than a general statement about "evolving market dynamics." That specificity is new — a year ago, most of this language was still hedged.

One Company in the Same Data Set Says It Isn't Happening

Medtronic names pharmaceutical pressure on bariatric procedure volumes directly in its MD&A. Insulet, asked about a soft quarter in its type 2 diabetes business, went the other way:

"This isn't due to pricing. This isn't due to competition. This isn't due to GLP-1s. This is due to our execution in serving the type 2 community in the first 90 days." (PODD)

Insulet is the only device maker in this set that denies GLP-1 adoption is a factor in its numbers, while marketing an ecosystem strategy built on CGM-plus-algorithm integration that assumes patients stay on device therapy alongside a drug. Whether that's a genuine operational read or a company avoiding a harder conversation is exactly the kind of thing worth watching filing to filing, not settling on one call.

Then It Shows Up in a Chemicals Filing and an Automation Call

This is where it gets interesting for anyone not already tracking pharma and medtech. International Flavors & Fragrances is positioning appetite suppression as a product opportunity rather than a threat to its ingredients business:

"Instead of looking at these as negatives, as we've looked at them as opportunities and have been very proactively both on GLP-1s and the overall move to higher protein consumer products." (IFF)

Celanese is sizing a market around the pill itself, in a chemicals-company Q&A:

"The growth rates that we called out and the size of markets does contemplate based upon discussions with our customers, kind of GLP-1 pills and what that means going forward." (CE)

And Rockwell Automation, an industrial automation supplier with no direct exposure to either the drug or the device side, is fielding analyst questions about it because of what oral dosing does to manufacturing lines:

"Oral solid dose variants of GLP-1 is an important innovation that's driving a lot of need for additional automation." (ROK)

None of these three companies sell a GLP-1 drug or a device that competes with one. All three are now describing it as a line item in how they talk about growth.

It's Also Embedded in the Boilerplate, Not Just the Prepared Remarks

Hims & Hers' forced exit from compounded semaglutide is the most consequential single event in this data set, and the language describing it now appears not just in prepared remarks but inside the accounting policy notes:

"We evolved our United States weight loss offering to match our global approach towards providing access to branded GLP-1 medications, and offering access to compounded GLP-1 medications through our platform on a limited scale." (HIMS)

GoodRx has folded the same shift into its own revenue description:

"GoodRx has become one of the leading consumer access channels for GLP-1 medications in the U.S., giving manufacturers a scaled way to turn pricing strategies into consumer access." (GDRX)

And Phreesia — an EHR-adjacent patient engagement platform, not a pharmacy or a device maker — is now running paid-media case studies against GLP-1 prescriptions as a sales point:

"A 4% incremental lift in new-to-brand prescriptions versus a matched control group. More than 1,000 new patient starts versus a matched control group." (PHR)

Three companies with three different business models — consumer telehealth, prescription discounting, clinical software — all citing the same drug class as a growth driver in language written for investors, not patients.

Restaurants Are Fielding a Question Nobody Asked Them, With Data

McDonald's handles it the way most consumer companies still do, as an abstract risk factor:

"Health, environmental and other scientific studies and practices (such as changes to dietary guidelines or use of weight-loss medications), continuously evolve and may have contradictory implications, drive popular opinion, regulation, and alter consumer behavior." (MCD)

Krispy Kreme answered the same underlying question with a number instead of a hedge:

"Krispy Kreme consumers who use these medications are just as likely as non-users to purchase sweet treats for holidays and special occasions... typically purchased 2 to 3 times per year, primarily for sharing occasions." (DNUT)

That's a direct rebuttal, with data, of the demand-destruction narrative most consumer-staples risk factors gesture at without testing. Whether it holds up past this cycle is a different question, but it's a materially different disclosure than McDonald's boilerplate sitting right next to it.

The Market-Sizing Language Follows the Same Two Patterns

Pfizer sized the obesity opportunity behind its own pipeline candidate the way a lot of TAM claims get made — a large number, no penetration rate, no denominator explained:

"A market expected to reach $150 billion. Data we shared recently at the American Diabetes Association Scientific Sessions reinforce why we are excited about berobenatide." (PFE)

Celanese's device-component sizing is smaller and narrower by comparison — a $500 million estimate built around what its own customers are telling it about pill demand, not a category-wide figure borrowed from a research firm. Readers who want the fuller framework for telling those two kinds of claims apart — scale-setting versus a testable, boundable market — should read Total Addressable Market, in Management's Own Words, which walks through the same discipline across enterprise software and consumer staples.

Pulled individually, none of these mentions is remarkable. Stacked across Medical Devices, Biotech & Pharma, Healthcare Technology, Chemicals & Materials, Industrials & Manufacturing, and Restaurants, they read as one adoption curve moving through the economy at different speeds and in different directions depending on who's sitting on which side of it. The full evidence feed, company list, and bear case are on the GLP-1 Device Crossover hot topic page, updated as new filings land.